Neural Regeneration Research ›› 2026, Vol. 21 ›› Issue (10): 4769-4776.doi: 10.4103/NRR.NRR-D-25-00903

Previous Articles     Next Articles

Neuroinflammation and noradrenergic modulation with β2-adrenoceptors: Emerging therapeutic targets for Parkinson’s diseases

Maria Micaelle Gomes Tavares1, 2, Milena Caroline Nunes Monteiro de Carvalho1, 2, Mylaine Santos Mendonça1, 2, Iasmin de Carvalho Dantas1, Katty Anne Amador de Lucena Medeiros1, 3, José Ronaldo dos Santos1, Auderlan Mendonça de Gois1, *   

  1. 1Behavioral and Evolutionary Neurobiology Laboratory, Department of Biosciences, Federal University of Sergipe, Itabaiana, SE, Brazil; 
    2Department of Physiology, Federal University of Sergipe, São Cristóvão, SE, Brazil; 
    3Nursing Department, Federal University of Sergipe, Lagarto, SE, Brazil
  • Online:2026-10-15 Published:2026-06-12
  • Contact: Auderlan Mendonça de Gois, PhD, auderlan.m@gmail.com.
  • Supported by:
    This work was supported by fellowships from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil (CAPES), Fundação de Apoio à Pesquisa e à Inovação Tecnológica de Sergipe (FAPITEC/SE. Grant 019203.03295/2025-0), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, Grant 420458/2023-9) and the Pró-reitoria de Pesquisa da Universidade Federal de Sergipe (POSGRAP/UFS) (to AMG). JRS is the recipient of research fellowships from FAPITEC/SE. Grants 019203.04917/2023-5 e CNPq Grants 312863/2022-5.

Abstract: Neurodegenerative disorders, such as Parkinson’s disease, are strongly influenced by neuroinflammatory processes and dysfunction of the locus coeruleus-noradrenergic system. The locus coeruleus-noradrenergic system plays a pivotal role in modulating neuroinflammation and maintaining homeostatic regulation in the central nervous system. This review discusses the structural and functional aspects of the locus coeruleus-noradrenergic system and its interaction with immune responses. We examine how neuroinflammation contributes to disease progression, with a focus on glial activation and peripheral-central immune communication. Additionally, we analyze the impact of β-adrenoceptor-targeting drugs, highlighting the contrasting roles of β-blockers and β2-adrenoceptor agonists in neurodegeneration. While β-blocker, particularly non-selective agents like propranolol, have been associated with exacerbated neuroinflammation and Parkinson’s disease risk, β2-adrenoceptor agonists demonstrate neuroprotective effects by modulating microglial phenotypes, reducing α-synuclein aggregation, and enhancing neurotrophic support. Finally, we explore the canonical and non-canonical β2-adrenoceptor signaling pathways implicated in neuroprotection. Collectively, this review supports β2-adrenoceptors as promising therapeutic targets and underscores the need for further studies to elucidate their mechanistic roles in modulating neurodegenerative processes.

Key words: β-adrenergic, catecholamines, microglial cells, neurodegenerative disease, neuroprotection